Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Spotlight: Embolx Believes Balloon Microcatheter Occlusion Will Be A 'Breakthrough' For BPH, Cancer

Executive Summary

Embolx is having a big year. US FDA cleared its Sniper balloon occlusion microcatheter for pressure-directed arterial embolization a few months after the UK's NICE issued recommendations supporting prostate artery embolization for lower urinary tract symptoms caused by benign prostatic hyperplasia. Now the company is focused on improving market penetration by investing in physician-education and supporting research on new applications of targeted embolization, hoping to attract commercial partners or a possible acquirer.

You may also be interested in...



J&J Has Big Plans For Robotic Surgery In 2020

The company’s leadership discussed its recent investments in robotic surgery technology during Johnson & Johnson’s 2019 fourth-quarter earnings call on 22 January. The company will provide more information on its robotic surgery platforms at its investors meeting in May in New York.

NANS 2020: Medtronic’s DTM Spinal Cord Stimulation Relieves Back Pain In Trial

Three-month results from a 94-patient randomized trial of Medtronic’s Intellis spinal cord stimulation system showed superior back-pain relief with the differential target multiplexed waveform compared to conventional spinal cord stimulation.

2019 Device Approvals Review: Original PMAs Up, De Novos Down

The US FDA approved fewer novel devices in 2019 than in 2018, despite a slight increase in original PMA approvals. De novo clearances were down significantly after four straight years of increases, while panel-track PMA supplements and 510(k) clearances also declined from the 2018 totals.

Topics

UsernamePublicRestriction

Register

MT123052

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel